



**Wednesday, November 21<sup>st</sup>, 2018**

Dorothy Nadolny Cardio-Metabolic Disease Research Hub  
hosts School II of TREATMENT

## **The epidemic of fatty liver diseases: risk factors, treatment and extrahepatic consequences**

**Tayarut hall, Hadassah Medical Center, Ein Kerem**

### **08:40 Gathering and breakfast**

09:00-09:30 **Ilan Matok** (HUJI, Israel)  
Statistic analyses of large data

09:30—09:40 **Rifaat Safadi** (Hadassah, Israel): Greetings and overview of the  
fatty liver epidemics.

### **Liver signaling in the transition from NAFLD to NASH**

*Chair: Rifaat Safadi*

9:40-10:20 **Raul Mendez** (IRB, Spain)  
Translational regulation of the adaptive liver stress response

10:20-10:45 **Angela Valverde** (CSIC-UAM, Spain)  
Novel players in the progression and treatment of non-  
alcoholic liver disease associated to obesity

10:45-11:10 **Oren Tirosh** (HUJI, Israel)  
Lipotoxicity and hypoxic signaling in NAFLD progression

### **11:10-11:30 Coffee break**

## Modulation of liver metabolism by drugs and other interventions

*Chair: Isabel Fabregat*

- 11:30-11:55      **Yaacov Bar Tana** (HUJI, Israel )  
Fatty liver – More than liver pathology
- 11:55-12:20      **Yossi Tam** (HUJI, Israel )  
Reversal of fatty liver by peripheral CB1 receptor blockade is Sirt1/PPAR $\alpha$  dependent
- 12:20-12:45      **Sigal Fishman** (TLVMC, Israel)  
Glucose dependent insulinotropic polypeptide (GIP), a new player in the combat against obesity and NAFLD
- 12:45-13:10      **Shira Zelber Sagi** (Haifa U & TLVMC, Israel)  
NAFLD as a lifestyle oriented and treated disease

### **13:10-14:00 Lunch break**

- 14:00-14:45      **Shai Melcer** (CEO of BioHouse, Israel)  
From bench to business- visit to the Biohouse

## Subversion of fatty liver by nutrition and beyond

*Chair: Oren Shibolet* (TLVMC, Israel)

- 14:45-15:25      **Elisabetta Bugianesi** (UDT, Italy)  
The clinical spectrum of NAFLD
- 15:25-15:50      **Yftach Gepner** (TAU, Israel)  
Diet-induced hepatic fat content loss; benefits beyond concurrent decreases in visceral adiposity
- 15:50-16:15      **Eyal Shteyer** (SZMC, Israel)  
Fatty liver in children- is it different than in adults?
- 16:15-16:40      **Oren Shibolet** (TLVMC, Israel)  
Drug induced lipotoxicity
- 16:40-17:05      **Isabel Fabregat** (BU, Spain)  
TGF-beta: a targetable pathway in liver diseases?
- 17:05-17:30      **Jan Eriksson** (UU, Sweden) Clinical trials in NAFLD and the implications for patients receiving antipsychotic drug
- 17:30-17:40      **Boaz Tirosh** (HUJI, Israel)  
Concluding remarks

Organized by:

Boaz Tirosh (HUJI), Shira Zelber Sagi (Haifa U & TLVMC)